Skip to main content
. 2018 Feb 23;32(7):1609–1620. doi: 10.1038/s41375-018-0035-y

Table 1.

Clinical and molecular characteristics of the patients enrolled in this study (N = 395)

Parameter Value
Age Median 59.35 (range, 16–92)
Sex 185/395 patients were female (46.8%)
210/395 patients were male (53.2%)
De novo AML 307/372 patients (82.5%)
AML secondary to myelodysplastic syndrome 43/372 patients (11.6%)
AML secondary to other myeloid neoplasms 4/372 patients (1.1%)
Therapy-related AML 18/372 patients (4.8%)
WBC (mean) 28.140/mm3 (100–171.00/mm3)
WBC count greater than 30,000/mm3 46/154 patients (29.9%)
WBC count greater than 100,000/mm3 12/154 patients (7.8%)
European LeukemiaNet (ELN) low risk [37] 35/352 patients (8.9%)
European LeukemiaNet (ELN) intermediate 1 risk [37] 100/352 patients (28.4%)
European LeukemiaNet (ELN) intermediate 2 risk [37] 80/352 patients (22.7%)
European LeukemiaNet (ELN) high risk [37] 137/352 patients (38.9%)
Chemotherapy in induction 251/308 patients (81.5%)
  Gemtuzumab Ozagomicin was added 42/251 patients (16.7%)
  Complete remission 153/251 patients (60.9%)
Hematopoietic stem cell transplant 85/283 patients (30.0%)
Loss or a mutation of TP53 at diagnosis 63/395 patients (15.9%)
  Loss 29/395 patients (7.3%)
  Mutation 53/324 patients (16.4%)
Internal tandem duplication in FLT3 42/298 patients (14.1%)
Tyrosine kinase domain mutation in FLT3 18/298 patients (6.0%)
Mutations in NPM1 gene 50/286 patients (17.5%)
Mutations in IDH1 gene 4/121 patients (3.3%)
Mutations in IDH2 gene 11/135 patients (8.3%)
Mutations in DNMT3A gene 7/38 patients (19.4%)
Mutations in CEBPA gene 5/106 patients (4.7%)
Mutations in RUNX1 gene 11/87 patients (12.6%)
Mutations in CBL gene 2/91 patients (2.2%)
Mutations in NRAS gene 10/95 patients (10.5%)